Tricida, Inc. TCDA
We take great care to ensure that the data presented and summarized in this overview for Tricida, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TCDA
Top Purchases
Top Sells
About TCDA
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at TCDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2022
|
David P Bonita Director |
SELL
Open market or private sale
|
Indirect |
3,629,226
-100.0%
|
$0
$0.22 P/Share
|
|
Nov 25
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
3,629,226
-100.0%
|
$0
$0.22 P/Share
|
|
Nov 23
2022
|
David P Bonita Director |
SELL
Open market or private sale
|
Indirect |
5,617,300
-60.75%
|
$0
$0.21 P/Share
|
|
Nov 23
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
5,617,300
-60.75%
|
$0
$0.21 P/Share
|
|
Nov 23
2022
|
Robert J Alpern Director |
SELL
Open market or private sale
|
Direct |
131,879
-100.0%
|
$0
$0.21 P/Share
|
|
Nov 22
2022
|
David P Bonita Director |
SELL
Open market or private sale
|
Indirect |
1,034,421
-10.06%
|
$0
$0.22 P/Share
|
|
Nov 22
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
1,034,421
-10.06%
|
$0
$0.22 P/Share
|
|
Nov 21
2022
|
Robert J Alpern Director |
SELL
Open market or private sale
|
Direct |
27,584
-17.3%
|
$0
$0.23 P/Share
|
|
Oct 26
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,367,174
-38.69%
|
$0
$0.46 P/Share
|
|
Oct 25
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,970,418
-24.36%
|
$0
$0.57 P/Share
|
|
Oct 24
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,113,948
-20.72%
|
$0
$0.61 P/Share
|
|
Oct 19
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
311,466
+1.5%
|
$3,114,660
$10.77 P/Share
|
|
Oct 18
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,400
+0.41%
|
$444,400
$11.98 P/Share
|
|
Oct 17
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
170,292
+1.7%
|
$1,873,212
$11.67 P/Share
|
|
Oct 13
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,674
+0.05%
|
$51,414
$11.98 P/Share
|
|
Oct 13
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,332
-0.71%
|
$322,652
$11.99 P/Share
|
|
Oct 12
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
212,283
-4.81%
|
$2,547,396
$12.53 P/Share
|
|
Oct 11
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
118,385
-2.6%
|
$1,420,620
$12.01 P/Share
|
|
Oct 11
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.26%
|
$275,000
$11.85 P/Share
|
|
Oct 10
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,314
+0.83%
|
$883,454
$11.89 P/Share
|